To the Editor Shah et al1 conducted an important study to evaluate the 1-year safety and patency of the interatrial shunt device (IASD) compared with a sham control treatment. The IASD appears to be safe with respect to various clinical end points. For one of the key outcomes, heart failure (HF) events requiring intravenous treatment, the authors reported the cumulative incidence of HF events over the first year of the trial in Figure 2B.1 The HF event rates at the end of follow-up were 19% in the IASD arm and 41% in the control arm (log-rank P = .08). The authors also stated that Figure 2B1 shows that there was a longer time from randomization to first HF event in the IASD arm (mean [SD] time, 178  days) vs the control arm (mean [SD] time, 70  days).
McCaw ZR, Kim DH, Wei L. Evaluating Treatment Effect of Transcatheter Interatrial Shunt Device Using Heart Failure Event Rates. JAMA Cardiol. 2019;4(3):299. doi:10.1001/jamacardio.2019.0001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: